Freestone Grove Partners LP Stoke Therapeutics, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 18,049 shares of STOK stock, worth $157,748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,049Holding current value
$157,748% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
136Shares Held
57.3MCall Options Held
5.7KPut Options Held
24.4K-
Skorpios Trust6.91MShares$60.4 Million99.8% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$47.3 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$45.3 Million22.22% of portfolio
-
Rtw Investments, LP New York, NY5.12MShares$44.8 Million0.92% of portfolio
-
Baker Bros. Advisors LP New York, NY4.63MShares$40.5 Million0.57% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $345M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...